Filing summary
Issuer identification discrepancy: The request identifies ACCENDRA HEALTH INC, but the supplied Form 10-Q is for Owens & Minor, Inc. (NYSE: OMI), for the quarter ended June 30, 2022. This summary reflects the filing text provided; verify the issuer and filing before relying on it.
Business context and reporting period
Owens & Minor distributes medical and surgical products, provides outsourced logistics and related services, and supplies home healthcare products and services. It reports two segments: Products & Healthcare Services and Patient Direct. On March 29, 2022, it acquired Apria, a home healthcare provider, for approximately $1.7 billion net of cash acquired. Apria is included in Patient Direct from the acquisition date. Prior-year segment results were recast to the new reporting structure.
Unless noted otherwise, financial amounts below are in U.S. dollars. The quarter and six-month periods ended June 30, 2022 are compared with the corresponding 2021 periods.
Key financial metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net revenue | $2,500.0 million | $2,489.5 million | $4,907.0 million | $4,816.0 million |
| Gross margin | $532.5 million (21.30%) | $400.1 million (16.07%) | $906.0 million (18.46%) | $842.8 million (17.50%) |
| Operating income | $75.1 million | $96.9 million | $136.1 million | $243.6 million |
| Net income | $28.6 million | $65.9 million | $67.9 million | $135.5 million |
| Diluted EPS | $0.37 | $0.87 | $0.89 | $1.80 |
| Interest expense, net | $35.8 million | $11.5 million | $47.9 million | $25.2 million |
For the six months, cash from operations was $169.5 million, versus $12.4 million a year earlier. Investing activities used $1,745.3 million, principally reflecting the Apria acquisition; financing activities provided $1,580.6 million. Cash, cash equivalents and restricted cash totaled $73.0 million at June 30, 2022, including $16.6 million of restricted cash.
At June 30, 2022, total debt was $2,576.4 million, including $2,565.6 million of long-term debt and $10.8 million of current maturities. Cash and cash equivalents were $56.4 million. The company had $422 million available under its $450 million revolving facility and reported compliance with debt covenants. Total current assets were $2,434.2 million and current liabilities were $1,569.4 million.
Material changes versus prior periods
- Q2 revenue increased 0.4%; six-month revenue increased 1.9%. Patient Direct revenue rose 145.1% in Q2 and 87.6% for six months, mainly from Apria and Byram growth. Products & Healthcare Services revenue declined 14.6% in Q2 and 7.0% for six months, reflecting lower hospital demand and reduced glove cost pass-through.
- Gross margin increased in dollars and as a percentage of revenue, aided by Apria and sales mix. Nevertheless, operating income and net income fell: DS&A expense rose 54.0% in Q2, while net interest expense more than tripled, primarily due to acquisition-related debt.
- Six-month results included $41.2 million of acquisition-related and exit/realignment charges, versus $14.6 million a year earlier. The 2021 comparison included a $40.4 million loss on extinguishment of debt; no such loss was recorded in 2022.
- Debt rose substantially to fund Apria. Total assets increased to $5,555.3 million from $3,536.6 million at December 31, 2021, including acquisition-related goodwill and intangible assets.
Outlook, risks and unusual items
- The filing provides no specific numerical revenue, earnings, or cash-flow guidance. Management said available financing sources and operating cash generation were expected to be sufficient for foreseeable funding needs, while noting economic conditions could affect counterparties and borrowing costs.
- Management cited inflation, labor and transportation costs, supply-chain challenges, interest rates, lower hospital demand, and uncertainty about passing higher costs to customers. COVID-19-related disruption and demand remain difficult to predict.
- The Philips Respironics Class I recall affects certain respiratory devices distributed by Apria. The filing warns of possible unrecoverable costs, device shortages, reduced use or demand, and adverse effects on revenue, earnings, cash flows, and liquidity.
- The company estimates that a 100-basis-point rise in interest rates would reduce future annual pretax earnings by approximately $8.8 million, after considering its interest-rate swap. It also discloses exposure to raw-material, freight, fuel, and foreign-currency volatility.
- An IRS dispute concerns transfer pricing for tax years 2015–2018. Management believes reserves are adequate and does not expect a material impact, but notes an adverse outcome could be material. The Apria purchase-price allocation remained preliminary; acquired goodwill was approximately $1.3 billion and was not expected to be tax deductible.
- Management concluded disclosure controls were effective as of June 30, 2022. Its evaluation excluded Apria’s internal controls during the permitted post-acquisition period.
Important facts for investors to verify
- Confirm that the intended filing is Owens & Minor’s 2022 second-quarter 10-Q, not an Accendra Health filing.
- Assess whether Patient Direct growth and Apria integration can offset continuing weakness in Products & Healthcare Services, and review Apria’s contribution, including its reported $30.3 million net loss since acquisition.
- Review debt service, variable-rate exposure, covenant headroom, and scheduled maturities, including substantial maturities in 2029 and 2030.
- Monitor the Respironics recall, device availability, reimbursement exposure, and any financial recovery from the manufacturer.
- Track working-capital trends: DSO rose to 26.0 days from 24.6, and inventory days rose to 70.5 from 64.7.